Brief: Telix Pharmaceuticals Limited Reports Qtrly Group Revenue Of $245 Million
Wed 01:57
BRIEF-Telix Pharmaceuticals Limited Reports Qtrly Group Revenue Of $245 Million Oct 21 (Reuters) - Telix Pharmaceuticals Limited TLX.AX:
QTRLY GROUP REVENUE OF US$245 MILLION
REAFFIRMED THAT FY 2026 REVENUE AND OTHER INCOME IS EXPECTED TO BE IN EXCESS OF US$1 BILLION
REVENUE TRACKING IN LINE WITH UPPER END OF FY 2026 GUIDANCE OF US$950 MILLION TO US$970 MILLION PLUS US$40 MILLION OF OTHER INCOME
REVISES FY 2026 RESEARCH AND DEVELOPMENT EXPENDITURE GUIDANCE RANGE TO US$240 MILLION TO US$260 MILLION
Further company coverage: TLX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Telix Pharmaceuticals
See all newsJefferies cuts price target on Telix Pharmaceuticals following quarterly update
Australia's Telix Pharmaceuticals slides on sequential fall in quarterly revenue
Brief: Telix Pharmaceuticals Limited Reports Qtrly Group Revenue Of $245 Million
Education Agreement To Advance Psma-Informed Prostate Care
Australia's Telix rises after dosing first US patients with brain cancer imaging drug